以结肠镜为载体的针刺麻醉循证研究

注册号:

Registration number:

ITMCTR2025001361

最近更新日期:

Date of Last Refreshed on:

2025-07-09

注册时间:

Date of Registration:

2025-07-09

注册号状态:

Registration Status:

补注册

Retrospective registration

注册题目:

以结肠镜为载体的针刺麻醉循证研究

Public title:

An evidence-based study on acupuncture anesthesia using colonoscopy as a carrier

注册题目简写:

结肠镜下针刺麻醉研究

English Acronym:

Research on acupuncture anesthesia during colonoscopy

研究课题的正式科学名称:

以结肠镜为载体的针刺麻醉循证研究

Scientific title:

An evidence-based study on acupuncture anesthesia using colonoscopy as a carrier

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

张木子

研究负责人:

王春艳

Applicant:

Muzi Zhang

Study leader:

Chunyan Wang

申请注册联系人电话:

Applicant telephone:

18840164230

研究负责人电话:

Study leader's telephone:

13512206486

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

zhangmz1097@163.com

研究负责人电子邮件:

Study leader's E-mail:

0208wcy@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

天津市河西区大营门街道广东路1号天津医科大学广东路校区

研究负责人通讯地址:

天津市河西区大营门街道广东路1号天津医科大学广东路校区

Applicant address:

Tianjin Medical University Guangdong Road Campus No.1 Guangdong Road Dayingmen Sub-district Hexi District Tianjin

Study leader's address:

Tianjin Medical University Guangdong Road Campus No.1 Guangdong Road Dayingmen Sub-district Hexi District Tianjin

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

天津医科大学

Applicant's institution:

Tianjin Medical University

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

IRB2024-YX-566-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

天津医科大学总医院学伦理委员会

Name of the ethic committee:

The Ethics Committee of Tianjin Medical University General Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2024/11/28 0:00:00

伦理委员会联系人:

金冬来

Contact Name of the ethic committee:

Donglai Jin

伦理委员会联系地址:

天津医科大学总医院

Contact Address of the ethic committee:

Tianjin Medical University General Hospital

伦理委员会联系人电话:

Contact phone of the ethic committee:

022-60361044

伦理委员会联系人邮箱:

Contact email of the ethic committee:

1020574175@qq.com

研究实施负责(组长)单位:

天津医科大学总医院麻醉科

Primary sponsor:

Department of Anesthesiology General Hospital of Tianjin Medical University

研究实施负责(组长)单位地址:

天津市和平区鞍山道154号

Primary sponsor's address:

No. 154 Anshan Road Heping District Tianjin

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

天津

市(区县):

Country:

China

Province:

Tianjin

City:

单位(医院):

天津医科大学总医院

具体地址:

天津市和平区鞍山道154号

Institution
hospital:

Tianjin Medical University General Hospital

Address:

No. 154 Anshan Road Heping District Tianjin

经费或物资来源:

现代中医药海河实验室科技项目

Source(s) of funding:

Scientific and Technological Project of Haihe Laboratory for Modern Traditional Chinese Medicine

研究疾病:

结肠镜下针刺麻醉

研究疾病代码:

Target disease:

Acupuncture anesthesia under colonoscopy

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

其它

Others

研究目的:

验证针刺麻醉能减少麻醉药物丙泊酚的需求量,从而降低麻醉药物的副作用风险,提高安全性

Objectives of Study:

To verify that acupuncture anesthesia can reduce the demand for the anesthetic drug propofol thereby lowering the risk of side effects of anesthetic drugs and enhancing safety

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

18≤年龄≤65岁,性别不限; 接受无痛结肠镜诊疗的患者; ASA评分为I级或II级; 18 kg/m2<BMI<28kg/m2

Inclusion criteria

Age ≥ 18 and ≤ 65 years old with no restriction on gender; Patients receiving painless colonoscopy diagnosis and treatment; ASA (American Society of Anesthesiologists) physical status classification of I or II; BMI (Body Mass Index) > 18 kg/m² and < 28 kg/m²

排除标准:

拟行气管插管(包括喉罩)的患者; 需要进行操作复杂的内镜诊疗技术; 有肠道狭窄或粘连病史的患者; 急性心力衰竭;不稳定型心绞痛;筛选前6个月内发生心肌梗死; 患有严重呼吸道病变的患者; 患有精神系统疾病及长期服用精神类药物史及认知功能障碍者; 被判定为呼吸道管理困难(改良马氏评分为IV级)患者; 肝肾等重要脏器功能严重受损的患者; 筛选期开始前2年内有药物滥用史、吸毒史和酗酒史,酗酒即每日平均饮酒超过2单位酒精(1单位=360 mL啤酒或45 mL酒精量为40%的白酒或150 mL葡萄酒); 未接受正规降压治疗或血压控制不佳的患者(筛选期坐位收缩压≥160 mmHg或≤90mmHg,和/或筛选期舒张压≥100mmHg); 一个月内每天或近三个月内间断服用苯二氮卓类药物和/或阿片类药物; 对阿片类药物、丙泊酚等药物及其药物组分过敏或有禁忌者; 妊娠或哺乳期的女性; 3个月内有生育计划的患者(包括男性); 近3个月内作为受试者参加过任何临床试验; 研究者认为不宜参加此试验患者

Exclusion criteria:

Patients planned for endotracheal intubation (including laryngeal mask); Patients requiring complex endoscopic diagnostic and therapeutic procedures; Patients with a history of intestinal stenosis or adhesion; Patients with acute heart failure; unstable angina pectoris; myocardial infarction within 6 months prior to screening; Patients with severe respiratory lesions; Patients with psychiatric disorders a history of long-term use of psychiatric medications and cognitive dysfunction; Patients judged to have difficult airway management (Modified Mallampati Score of Grade IV); Patients with severely impaired functions of vital organs such as the liver and kidneys; Patients with a history of drug abuse drug addiction or alcoholism within 2 years prior to the screening period where alcoholism is defined as an average daily consumption of more than 2 units of alcohol (1 unit = 360 mL of beer or 45 mL of spirits with 40% alcohol content or 150 mL of wine); Patients who have not received regular antihypertensive treatment or have poorly controlled blood pressure (sitting systolic blood pressure ≥160 mmHg or ≤90 mmHg and/or sitting diastolic blood pressure ≥100 mmHg during the screening period); Patients taking benzodiazepines and/or opioids daily for a month or intermittently within the past three months; Patients allergic to or having contraindications for opioids propofol and other related drug components; Pregnant or lactating women; Patients (including males) planning to conceive within 3 months; Patients who have participated as subjects in any clinical trial within the past 3 months; Patients deemed unsuitable for participation in this trial by the investigator

研究实施时间:

Study execute time:

From 2024-11-29

To      2025-12-31

征募观察对象时间:

Recruiting time:

From 2025-01-01

To      2025-06-30

干预措施:

Interventions:

组别:

假针刺组

样本量:

60

Group:

sham acupuncture group

Sample size:

干预措施:

假针刺

干预措施代码:

02

Intervention:

sham acupuncture

Intervention code:

组别:

针刺组

样本量:

60

Group:

acupuncture group

Sample size:

干预措施:

针刺

干预措施代码:

01

Intervention:

acupuncture

Intervention code:

样本总量 Total sample size : 120

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

天津

市(区县):

Country:

China

Province:

Tianjin

City:

单位(医院):

天津医科大学总医院

单位级别:

三级甲等临床试验医院

Institution/hospital:

Tianjin Medical University General Hospital

Level of the institution:

Grade 3 Class A Clinical Trial Hospital

测量指标:

Outcomes:

指标中文名:

丙泊酚每公斤体重用量

指标类型:

次要指标

Outcome:

Dosage of propofol per kilogram of body weight

Type:

Secondary indicator

测量时间点:

镇静诱导给药开始至肠镜检查结束

测量方法:

丙泊酚每公斤体重用量为从镇静诱导给药开始至肠镜检查结束的丙泊酚注射液给药总量除以患者体重

Measure time point of outcome:

From the start of sedation induction administration to the end of colonoscopy

Measure method:

The dosage of propofol per kilogram of body weight is calculated by dividing the total amount of propofol injection administered from the start of sedation induction to the end of colonoscopy by the patient's body weight

指标中文名:

镇静质量评价

指标类型:

次要指标

Outcome:

Evaluation of sedation quality

Type:

Secondary indicator

测量时间点:

接受肠镜诊疗全程

测量方法:

改良阿姆斯特丹术前焦虑与信息量表(APAIS)​、镇静成功率​、镇静诱导时间​、生命体征监测​、脑电双频指数测量(BIS)​、镇静苏醒时间​、达离院标准时间

Measure time point of outcome:

Throughout the entire process of receiving colonoscopy diagnosis and treatment

Measure method:

Modified Amsterdam Preoperative Anxiety and Information Scale (APAIS)Success rate of sedationSedation induction timeMonitoring of vital signsBispectral Index (BIS) measurementSedation recovery timeTime to meet discharge criteria

指标中文名:

丙泊酚总用量及追加情况

指标类型:

次要指标

Outcome:

The total dosage of propofol and the administration of additional doses

Type:

Secondary indicator

测量时间点:

从镇静给药开始到肠镜操作结束

测量方法:

丙泊酚总用量​、丙泊酚追加量​、丙泊酚追加次数

Measure time point of outcome:

From the start of sedation administration to the completion of colonoscopy procedure

Measure method:

Total dosage of propofol​Additional dosage of propofol Number of additional administrations of propofol

指标中文名:

肠镜检查质量评价

指标类型:

次要指标

Outcome:

Evaluation of Colonoscopy Quality

Type:

Secondary indicator

测量时间点:

从肠镜插入肛门口开始至退出肠镜

测量方法:

结肠镜检查进镜时间和检查总时间肠镜检查成功率检查后疼痛视觉模拟评分(VAS)

Measure time point of outcome:

From the moment the colonoscope is inserted into the anus until it is withdrawn

Measure method:

Insertion time of colonoscopy​Total duration of colonoscopy examination (or simply Total colonoscopy time for brevity)​ Success rate of colonoscopy​Visual Analog Scale (VAS) for post-colonoscopy pain

指标中文名:

丙泊酚每公斤体重每分钟用量

指标类型:

主要指标

Outcome:

The dosage of propofol per kilogram of body weight per minute

Type:

Primary indicator

测量时间点:

镇静诱导给药开始至肠镜检查结束

测量方法:

计算用药量

Measure time point of outcome:

The period from the start of sedation induction administration to the completion of colonoscopy

Measure method:

Calculate the medication dosage

指标中文名:

麻醉安全性评价

指标类型:

次要指标

Outcome:

Evaluation of anesthesia safety

Type:

Secondary indicator

测量时间点:

丙泊酚注射液开始给药至受试者完全清醒期间

测量方法:

镇静低血压发生率​、镇静过程中呼吸抑制发生率

Measure time point of outcome:

The period from the start of propofol injection administration until the subject is fully awake

Measure method:

Incidence of hypotension during sedationIncidence of respiratory depression during sedation

指标中文名:

医患满意度评价

指标类型:

次要指标

Outcome:

Evaluation of patient and physician satisfaction

Type:

Secondary indicator

测量时间点:

肠镜检查结束后

测量方法:

麻醉医师操作满意度评价​、肠镜医师操作质量评价及满意度​、针灸医师总体满意度评分(VAS)​、患者满意度及复查意愿评估​、患者针刺接受度评估

Measure time point of outcome:

After the completion of colonoscopy

Measure method:

Evaluation of satisfaction with anesthesiologist's performanceEvaluation of endoscopist's (colonoscopist's) operational quality and satisfactionOverall satisfaction Visual Analog Scale (VAS) score for acupuncturistAssessment of patient satisfaction and willingness for follow-up examinationEvaluation of patient acceptability towards acupuncture

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 18
Min age years
最大 65
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

本研究采用不等段长分段随机(Unequaled size block Randomization),在纳入第一例患者之前,由计算机程序生成随机数字序列(Random Number Sequence),以分中心作为分层因素,段长在4或6之间取值;通过中央随机系统(Central Randomization System)索取分组信息。

Randomization Procedure (please state who generates the random number sequence and by what method):

This study adopts unequal-sized block randomization (Unequaled size block Randomization). Before the enrollment of the first patient a random number sequence is generated by a computer program with the sub-center (or study site) as the stratification factor and the block size taking values between 4 and 6. Grouping information is obtained through a central randomization system (Central Randomization System).

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

EDC系统https://ncrcacu-crdm.tjtcm.cn:88/#/

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

EDC System https://ncrcacu-crdm.tjtcm.cn:88/#/

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

本试验将使用EDC系统来执行数据输入。研究助理将通过EDC系统填写所有电子CRF。研究人员将检查eCRF。eCRF修改的痕迹将留在数据库中。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

This trial will utilize an EDC (Electronic Data Capture) system for data entry. Research assistants will complete all electronic CRFs (Case Report Forms) through the EDC system. Researchers will review the eCRFs. The modification records of the eCRFs will be retained in the database.

数据管理委员会:

Data Managemen Committee:

暂未确定

Not yet

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统